You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
  1. Lauren Lepone1,
  2. Renee N Donahue1,
  3. Italia Grenga1,
  4. James L Gulley2,
  5. Christopher R Heery1,
  6. Ravi A Madan3,
  7. Jeffrey Schlom1 and
  8. Benedetto Farsaci1
  1. Aff1 grid.48336.3a0000000419368075Laboratory of Tumor Immunology and BiologyCCR, NCI, NIH Bethesda MD USA
  2. Aff2 grid.48336.3a0000000419368075CCR, NCI, NIH Bethesda MD USA
  3. Aff3 grid.48336.3a0000000419368075Genitourinary Malignancies BranchCCR, NCI, NIH Bethesda MD USA

https://doi.org/10.1186/2051-1426-2-S3-P152

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Purpose

    Immunotherapies aiming to interfere with the immune checkpoint molecule PD-1 (programmed death-1) and its ligand PD-L1 are currently being investigated in several clinical trials to treat cancer patients. The PD-1 pathway is one of the ways cancer cells evade immune-mediated killing. As little is known about the expression of PD-1 and PD-L1 in cancer patients compared to normal individuals, the aim of this study was to assess PBMC subsets for expression of these markers.

    Methods

    Twelve immune cell subsets were analyzed by flow-cytometry in 22 cancer patients and 16 normal individuals. The cancer patients consisted of 1 anal, 2 breast, 4 colon, 1 esophageal, 2 mesothelioma, 1 neuroendocrine, 1 non-small cell lung, 1 ovarian, 5 pancreatic, 3 renal cell and 1 squamous cell tracheal cancer patients. The subsets analyzed were CD4 and CD8 T cells, B cells, conventional dendritic cells (cDC), plasmacytoid DC (pDC), natural killer cells (NK), natural killer T cells (NKT), myeloid derived suppressor cell (MDSC), monocytic MDSC (mMDSC), granulocytic MDSC (gMDSC), and lineage-negative MDSC (Lin-MDSC). We also analyzed surface expression of PD-1 (clone MIH4) and PDL-1 (clone MIH1). See Figure 1.

    Figure 1
    Figure 1

    Differences in PBMC subsets and PD-1 and PD-L1 expression in cancer patients at baseline and normal individuals.

    Results

    Compared to normal subjects, cancer patients had some PBMC subsets with changes in frequency but no differences in PD-1 and PD-L1 expression (i.e., B cells, mMDSCs, and gMDSCs). Other subsets showed changes in PD-1 and PD-L1 expression without differences in the frequency of the subset (i.e., CD4, Tregs, cDCs, pDCs, NK, and MDSCs). Lin-MDSCs presented at a higher frequency and greater PD-L1 positivity.

    Conclusions

    Understanding the differences of PBMC immune subsets between normal subjects and cancer patients, and the surface expression of PD-1 and PD-L1, can provide insights as to which immune subsets can be targeted by therapies aimed at interfering with the PD-1 pathway in cancer patients.